Enoxaparin
Enoxaparin 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Venous Thromboembolism (VTE)。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
14 项
已进入 III/IV 期
24 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Regeneron Pharmaceuticals
- Medical University of Vienna
- Loewenstein Hospital
- Military Hospital of Tunis
- Qilu Hospital of Shandong University
- Mayo Hospital Lahore
- Medical University of Gdansk
- University Hospital, Motol
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
奥地利、Israel、Tunisia、中国、Pakistan、Poland、Czechia、美国、Brazil、加拿大、Mexico、Bulgaria
正在招募患者的 Enoxaparin 研究
Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients
不适用招募中奥地利NCT06357403Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury
不适用招募中IsraelNCT05484557Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty
不适用招募中TunisiaNCT07869615The Clinical Features and Pregnancy Outcomes of CTD Patients
不适用招募中中国NCT04918524Treatment and Clinical Outcomes Among SLE Patients in Pregnancy
I 期招募中中国NCT04976465Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention
IV 期招募中PakistanNCT07243080Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
不适用招募中PolandNCT07270263Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation
不适用招募中CzechiaNCT06868823Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support
IV 期招募中奥地利NCT06442267Apixaban or Enoxaparin After Head and Neck Cancer Surgery
IV 期招募中美国NCT07189897AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
III 期招募中美国Brazil加拿大MexicoNCT05848713REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
III 期招募中美国BulgariaHungary日本NCT07015905STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
IV 期招募中加拿大NCT05255003Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery
IV 期招募中加拿大芬兰挪威NCT05245877THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
IV 期招募中英国NCT05735639Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk
IV 期招募中法国NCT06845423Effect of LMWH on Neonatal Outcomes in Isolated Oligohydramnios
IV 期招募中PakistanNCT07907731Randomized Assessor-Masked Trial of Moderate Graduated Compression Stockings for Popliteal Vein Dilation During Long-Haul Economy-Class Air Travel After Aesthetic Surgery
不适用招募中ColombiaNCT07810192Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis
III 期招募中瑞士NCT07140211Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery
不适用招募中EgyptNCT06689241Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)
IV 期招募中美国NCT04861103Optimizing Anticoagulation in Pregnancies With Mechanical Heart Valves
不适用招募中加拿大NCT07658989Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
IV 期招募中EgyptNCT07132515Evaluation of the Efficacy of an inTerdialytic "Ethanol 40% v/v - enoxapaRin 1000 U/mL" Lock solutioN to Prevent Tunnelled Catheter Infections in Chronic Hemodialysis Patients
III 期招募中法国NCT03083184
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。